DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B Cell Lymphomas

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0919
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Genetic Background and Evolution of Relapses in Aggressive B-Cell Lymphomas

Haematologica
Hematology
2017English

The Aggressive Peripheral T-Cell Lymphomas: 2017

American Journal of Hematology
Hematology
2017English

Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment

Biomedical Sciences
2017English

Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas

Cancers
Cancer ResearchOncology
2020English

Cell Cycle Deregulation in B-Cell Lymphomas

Blood
BiochemistryImmunologyCell BiologyHematology
2003English

Treatment of High Risk Aggressive B Cell Lymphomas With Da Epoch R- The Austrian Experience

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Double-Hit B-Cell Lymphomas

Blood
BiochemistryImmunologyCell BiologyHematology
2011English

The Dial Study (Dual Immunomodulation in Aggressive Lymphoma): Randomized Phase 2 Trial of Varlilumab Plus Nivolumab in Relapsed/Refractory Aggressive B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

HLA Dependent Immune Escape Mechanisms in B-Cell Lymphomas: Implications for Immune Checkpoint Inhibitor Therapy?

OncoImmunology
OncologyAllergyImmunology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy